Skip to main content

news

Indian law firm S&R Associates has advised Glenmark Pharmaceuticals on the proposed divestment of 75 percent stake in Glenmark Life Sciences (GLS) for $680 million to Nirma, which was represented by Khaitan & Co.

GLS, which is a manufacturer and supplier of Active Pharmaceutical Ingredients (APIs) to global pharma manufacturers, was advised by Trilegal.

Pursuant to the transaction, Nirma will make a mandatory open offer to all public stakeholders of GLS. Glenmark Pharma will continue to own 7.84 percent of GLS.

The S&R team representing Glenmark Pharma was led by corporate partners Rajat Sethi and Pratichi Mishra, and included antitrust head Simran Dhir, tax partner Sumit Bansal and banking and finance partner Divyanshu Pandey.

The Khaitan team that represented Nirma was led by M&A partners Aashutosh Sampat and Mehul Shah and also included partners Arindam Ghosh (securities), Anisha Chand and Anshuman Sakle (competition), Shailendra Bhandare (IP), Abhiraj Gandhi (real estate) and Deepak Kumar (employment).

The Trilegal team representing GLS was led by the head of the corporate group, Yogesh Singh, along with partners Tejas Adiga and Atul Gupta.

“This deal aligns with our strategic intent of moving up the value chain to become an innovative/brand-led organisation, with continuous focus on our core therapeutic areas of dermatology, respiratory and oncology. It also presents an opportunity for us to strengthen shareholder value through deleveraging and enhancing our overall return profile,” Glenn Saldanha, chairman and managing director of Glenmark Pharma, said in a statement.

GLS will continue to operate as an independent API company under Nirma Limited, Yasir Rawjee, managing director and CEO of GLS, added.

 

TO CONTACT EDITORIAL TEAM, PLEASE EMAIL ALBEDITOR@THOMSONREUTERS.COM

Related Articles

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.

DMD, SAM guide $190 mln railway equipment deal

by Nimitt Dixit |

Shardul Amarchand Mangaldas & Co has advised Sona BLW Precision Forgings (Sona Comstar) on its $190 million agreement to acquire the Railway Equipment Division (RED) of Escorts Kubota (EKL), which was represented by DMD Advocates.